Member Since 2021
AOA Dx Inc
New York City Area
Oriana Papin-Zoghbi is the CEO and co-founder of AOA Dx Inc. She has global experience creating and leading organizations resulting in successful strategic exits. She brings a wealth of knowledge and expertise from women's health startups and large life science companies, and a passion for entrepreneurship and solving problems that disproportionality affects women. Oriana has received numerous awards in entrepreneurship, including the Massachusetts Life Sciences Center MassNextGen Award and The Wave Summit's Emerging Women Founder in Bio Award. As CEO of AOA Dx, she has raised over $2.5M in Seed funding and $500k in non-dilutive grant funding. She has been accepted into numerous competitive accelerators including Y Combinator, Springboard Enterprises and MassMedic Ignite. Known for her inspirational leadership, Oriana has a proven track record of developing a highly productive culture and turning visions into reality. She has a proven technical record of creating market entry strategies and product launches in new markets, including launching nationwide HPV screening in East Africa and novel diagnostics in maternal fetal medicine. Oriana holds a degree from Boston University in Economics and International Relations, and she has experience both living and working in various geographies.
Building the right co-founding team can make all the difference in both how your business succeeds and how you develop as a startup founder.
Since the many layoffs, firings and career pivots of 2020, many professionals have turned their sights toward entrepreneurship. Alongside the attraction of working for oneself came the opportunity to start fresh in a new space and maybe even a new industry altogether. For women, who were disproportionately affected by the economic impact of the pandemic, that meant the chance to enter fields which have historically been lacking female voices.
Raising money for any new venture will always come with its share of challenges.
AOA Dx Inc is a biotech company focused on early-stage cancer detection. AOA partnered with a leading oncology researcher at McGill University to develop the first early-stage ovarian cancer liquid biopsy diagnostic test. The co-founders have worked together for the last decade at two previous startups in the women’s health space, both resulting in successful exits upon commercialization. Ovarian cancer is the deadliest gynecological disease because there is no accurate testing method and its symptoms are continuously mistaken for benign conditions, making it incredibly difficult to diagnose the disease in the early stages. Early diagnosis will reduce patient mortality and deliver cost savings to payers. AOA, a Y combinator and VC backed company, raised a $2.5M Seed Round to accelerate development and clinical studies. Awards & Accelerators: 1. Y Combinator 2. Springboard Enterprises 3. MassMedic Ignite 4. Massachusetts Life Sciences Center MassNextGen 5. Wave Summit's Emerging Women Founder in Bio